Anixa Biosciences, Inc. is developing therapeutic and diagnostic programs that are focused on critical unmet needs in oncology and infectious disease. Anixa’s oncology programs are using the body’s immune system to take multiple approaches in fighting cancer—developing treatments, vaccines, and diagnostics. Anixa’s infectious disease program consists of a treatment for COVID-19 focused on inhibiting certain protein function necessary for viral replication.
We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
We are developing a revolutionary breast cancer vaccine technology focused on treating as well as preventing triple negative breast cancer (TNBC), the most lethal form of the disease.
We are developing a treatment for COVID-19 that is designed to inhibit protein function necessary for replication of SARS-CoV-2, the virus causing the disease.
Be The First to Receive Breaking NewsSign Up Now